ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

LOS ANGELES and SOLNA, Sweden and SHANGHAI: LOS ANGELES and SOLNA, Sweden and SHANGHAI, Dec. 14, 2021 /PRNewswire/ -- ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals, today announced that a 16-week, global, Phase 2 clinical trial of izokibep in patients with psoriatic arthritis (PsA) met its primary endpoint in a...

Click to view original post